Pretransplant HbA1c Is a Useful Predictor for the Development of New-Onset Diabetes in Renal Transplant Recipients Receiving No or Low-Dose Erythropoietin

Table 3

Risk factors for NODAT^a in patients receiving EPO^b ≤6,000 IU/week: multivariate analysis.

Variable	Univariate analysis			Multivariate analysis
	OR^c	95% CI^d	value	OR	95% CI	value
Recipient age [y]	1.05	0.99–1.11	0.10	1.05	0.99–1.13	0.09
Recipient gender	2.59	0.61–17.8	0.21	3.91	0.75–33.8	0.11
Donor age [y]	0.96	0.91–1.03	0.24
Pretransplant BMI^e	0.98	0.76–1.24	0.84
FPG^f [mg/dL]	1.02	0.94–1.09	0.68
HbA1c [%]	8.32	1.74–47.2	<0.01	9.18	1.64–64.5	<0.05
Dialysis period [mo]	1.01	0.99–1.02	0.33

New-onset diabetes after transplantation.
^bErythropoietin.
^cOdds ratio.
^d95% confidence interval.
^eBody mass index kg/m².
^fFasting plasma glucose.